PhosPrint selected as finalist for the SPIE Startup Challenge

December 12, 2022

Our consortium partner PhosPrint was selected as one of the finalists of the 13th annual SPIE Startup Challenge!

The SPIE Startup Challenge is an entrepreneurial pitch competition for new businesses that utilize optics and photonics to create innovative products, applications, and technologies. This year’s finalists include companies that are actively innovating in various fields, from healthcare to deep tech (including medical diagnostics, medical imaging, food safety, and display technology)

The final pitch presentations will take place at SPIE Photonics West in San Francisco on 31 January 2023, where PhosPrint and competitors will present their innovations. Finalists will compete for a top prize of $10,000. We’re fully supporting PhosPrint in their endeavour to win the Startup Challenge and wish our colleagues the best of success for their upcoming pitches!

More info: https://spie.org/news/2023-spie-startup-challenge-finalists-to-showcase-innovative-photonics-technologies-in-healthcare-and-deep-tech?utm_id=zliz

Other news
Tumor-LN-oC project has kicked-off!
August 18, 2021
On May 7th, 2021 Tumor-LN-oC project (Tumor and Lymph Node on Chip for cancer studies) was officially kicked-offvia online conferencing service where
Tumor-LN-oC´s first PRESS RELEASE
September 2, 2021
European (EU) H2020 funded Tumor-LN-oC project, officially started on 1st May, 2021, Tumor-LN-oC proposes the development and validation of tumor-lymph node-on
6 months completed!
November 24, 2021
On the 18th and 19th of November, the Tumor-LN-oC consortium met for the M6 meeting in Athens. The meeting closed the first half year of project implementation
Questionnaire for Tumor-LN-oC end-users
January 10, 2022
To better understand the end-user requirements for the tumor-lymph node-on-chip platform, that will be developed during the course of the project, we have prepa
Tumor-LN-oC completes selection of materials and processes
March 25, 2022
With the conclusion of Month 10 of the project, Tumor-LN-oC consortium successfully passed the second milestone of the project: the final selection of specifica